



## Correction: Evaluation of ERK as a therapeutic target in acute myelogenous leukemia


Ellen Weisberg · Chengcheng Meng · Abigail Case · Martin Sattler · Hong L. Tiv · Prafulla C. Gokhale · Sara Buhrlage · Jinhua Wang · Nathanael Gray · Richard Stone · Suiyang Liu · Shripad V. Bhagwat · Ramon V. Tiu · Sophia Adamia · James D. Griffin

Published online: 6 March 2020  
© Springer Nature Limited 2020

### Correction to: Leukemia

<https://doi.org/10.1038/s41375-019-0552-3>

Following the publication of this article, the authors noted minor errors in Supplementary Fig. 5. The correct version of this figure is included below along with the accompanying figure legend.



**Supplementary Fig. 5 LY3214996 potently inhibits proliferation of human primary patient AML cells in a concentration-dependent manner.** (A, B) Proliferation studies; 3-day LY3214996 treatment (A) or 6-day treatment (B) of primary AML patient samples. (C, D) Proliferation studies; 3-day LY3214996 treatment (C) or 6-day treatment (D)

of normal PBMCs versus human AML cells. (E) LY3214996 treatment of AML patient sample 14 for 3 days. (F-G) Proliferation studies; 3-day LY3214996 or AZD6244 treatment of AML patient samples 12 (F) and 13 (G). Patient and primagraft information for all samples shown in this manuscript is provided in Supplementary Tables 1 and 2.